Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (283)	4/6/1999 10:11:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3557

DAK: It is P&G not Merck. Yes, they have small burn rate. P&G pay (for licensed programs) all preclinical and early clinical programs. As example, P&G will pay for Axokine PI study, PIIa study (planed for summer), and if they decided to proceed further (large PII), they will share development cost and profit (if any). However, this year (based on new clinical trials with BDGF and NT-3) REGN will have higher expense than in 98. Miljenko PS: WP bailed out and price went down to 6. Now, Will see is there interest for accumulation or there is another unhappy investor(s)?